Marin et al. reported that CIK engineered with a specific CD19-CAR (including CD28 or 4-1BB costimulatory domains fused with CD3ζ signaling domain) presented higher cytotoxicity potential against B-ALL models than the CIK cells engineered with a CAR containing disulfide adapter protein 10 (DAP10) or CD3ζ domains alone [159,160]. The gene discussed is CD247; the disease is acute lymphoblastic leukemia.